Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Hoertel N, Sanchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, Becker KA, Reiersen AM, Lenze EJ, Seftel D, Lemogne C, Limosin F (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Molecular Psychiatry Springer Nature

DOI: 10.1038/s41380-021-01254-3

Authors with CRIS profile

Johannes Kornhuber Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) Université Fédérale de Toulouse Midi-Pyrénées FR France (FR) Universität Duisburg-Essen (UDE) DE Germany (DE) Washington University in St. Louis US United States (USA) (US) Golden Gate Fields US United States (USA) (US)

How to cite

APA:

Hoertel, N., Sanchez-Rico, M., Cougoule, C., Gulbins, E., Kornhuber, J., Carpinteiro, A.,... Limosin, F. (2021). Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01254-3

MLA:

Hoertel, Nicolas, et al. "Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms." Molecular Psychiatry (2021).

BibTeX: Download